Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

Abstract excerpt

Vaccines and drugs have helped reduce disease severity and blunt the spread of SARS-CoV-2. However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susceptibility of natural variants of the main protease (M pro /3CL pro ) of SARS-CoV-2 to protease inhibitors. Multiple...

Topics

Open a Topic to create a Post that cites this publication.

• Computational Drug Discovery Methods
• COVID-19 Clinical Research Studies
• Mosquito-borne diseases and control
• SARS-CoV-2 and COVID-19 Research
• SARS-CoV-2 detection and testing
• vaccines and immunoinformatics approaches
• Viral gastroenteritis research and epidemiology

Identifiers and source

Literature Corpus work

3675ccd6-db4d-5d48-95bf-986bb2b05220

DOI

10.1101/2022.08.07.503099